Galapagos NV (GLPG)
NASDAQ: GLPG · IEX Real-Time Price · USD
28.76
+0.13 (0.45%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Galapagos NV Revenue
In the year 2023, Galapagos NV had annual revenue of $266.36M with 3.78% growth. Revenue in the quarter ending December 31, 2023 was $-232.36M, a -255.08% decrease year-over-year.
Revenue (ttm)
$266.36M
Revenue Growth
+3.78%
P/S Ratio
7.12
Revenue / Employee
$237,186
Employees
1,123
Market Cap
1.90B USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 266.36M | 9.71M | 3.78% |
Dec 31, 2022 | 256.65M | -9.70M | -3.64% |
Dec 31, 2021 | 266.35M | -316.65M | -54.31% |
Dec 31, 2020 | 582.99M | -355.10M | -37.85% |
Dec 31, 2019 | 938.09M | 584.45M | 165.27% |
Dec 31, 2018 | 353.64M | 166.53M | 89.00% |
Dec 31, 2017 | 187.11M | 27.55M | 17.27% |
Dec 31, 2016 | 159.56M | 93.76M | 142.50% |
Dec 31, 2015 | 65.80M | -43.12M | -39.59% |
Dec 31, 2014 | 108.92M | -23.88M | -17.98% |
Dec 31, 2013 | 132.80M | 11.15M | 9.16% |
Dec 31, 2012 | 121.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Owens & Minor | 10.33B |
Amneal Pharmaceuticals | 2.39B |
Ginkgo Bioworks Holdings | 251.46M |
RxSight | 89.08M |
Recursion Pharmaceuticals | 44.58M |
NewAmsterdam Pharma Company | 15.66M |
Avidity Biosciences | 9.56M |
Fusion Pharmaceuticals | 2.07M |
GLPG News
- 22 days ago - Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024 - GlobeNewsWire
- 4 weeks ago - Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders' Meetings - GlobeNewsWire
- 4 weeks ago - Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board - GlobeNewsWire
- 2 months ago - Galapagos announces full year 2023 results and outlook for 2024 - GlobeNewsWire
- 2 months ago - Galapagos presents at EBMT-EHA annual meeting 2024 - GlobeNewsWire
- 3 months ago - Galapagos completes transaction to transfer Jyseleca® business to Alfasigma - GlobeNewsWire
- 4 months ago - Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S. - GlobeNewsWire
- 4 months ago - Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology - GlobeNewsWire